154 related articles for article (PubMed ID: 9575439)
1. [Fundamental studies on antibacterial activity of clindamycin against Propionibacterium acnes].
Komagata Y; Komiyama K; Nomura S
Jpn J Antibiot; 1998 Feb; 51(2):130-6. PubMed ID: 9575439
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of Propionibacterium acnes isolated from acne patients: comparative study of antimicrobial agents.
Nishijima S; Kurokawa I; Kawabata S
J Int Med Res; 1996; 24(6):473-7. PubMed ID: 8959531
[TBL] [Abstract][Full Text] [Related]
3. Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections.
Nenoff P; Haustein UF; Hittel N
Chemotherapy; 2004 Oct; 50(4):196-201. PubMed ID: 15452398
[TBL] [Abstract][Full Text] [Related]
4. Determination of the Mutant Prevention Concentration and the Mutant Selection Window of Topical Antimicrobial Agents against Propionibacterium acnes.
Nakase K; Nakaminami H; Toda Y; Noguchi N
Chemotherapy; 2017; 62(2):94-99. PubMed ID: 27764829
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany.
Alba V; Urban E; Angeles Dominguez M; Nagy E; Nord CE; Palacín C; Vila J
Int J Antimicrob Agents; 2009 Mar; 33(3):272-5. PubMed ID: 19095414
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes.
Kanayama S; Okamoto K; Ikeda F; Ishii R; Matsumoto T; Hayashi N; Gotoh N
J Infect Chemother; 2017 Jun; 23(6):374-380. PubMed ID: 28389164
[TBL] [Abstract][Full Text] [Related]
7. Effect of topical benzoyl peroxide/clindamycin versus topical clindamycin and vehicle in the reduction of Propionibacterium acnes.
Leyden JJ
Cutis; 2002 Jun; 69(6):475-80. PubMed ID: 12078851
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris.
Vogt K; Hermann J; Blume U; Gollnick H; Hahn H; Haustein UF; Orfanos CE
Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):943-5. PubMed ID: 1486893
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
Yamakawa T; Mitsuyama J; Hayashi K
J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
[TBL] [Abstract][Full Text] [Related]
10. In vivo antibacterial effects of tretinoin-clindamycin and clindamycin alone on Propionibacterium acnes with varying clindamycin minimum inhibitory.
Leyden JJ
J Drugs Dermatol; 2012 Dec; 11(12):1434-8. PubMed ID: 23377513
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of lipase activity in antibiotic-resistant propionibacterium acnes strains.
Gloor M; Wasik B; Becker A; Höffler U
Dermatology; 2002; 205(3):260-4. PubMed ID: 12399674
[TBL] [Abstract][Full Text] [Related]
12. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes.
Kuwahara K; Kitazawa T; Kitagaki H; Tsukamoto T; Kikuchi M
J Dermatol Sci; 2005 Apr; 38(1):47-55. PubMed ID: 15795123
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea.
Song M; Seo SH; Ko HC; Oh CK; Kwon KS; Chang CL; Kim MB
J Dermatol; 2011 Jul; 38(7):667-73. PubMed ID: 21352337
[TBL] [Abstract][Full Text] [Related]
14. Rapid systemic and local treatments with the antibacterial peptide dimer A3-APO and its monomeric metabolite eliminate bacteria and reduce inflammation in intradermal lesions infected with Propionibacterium acnes and meticillin-resistant Staphylococcus aureus.
Ostorhazi E; Voros E; Nemes-Nikodem E; Pinter D; Sillo P; Mayer B; Wade JD; Otvos L
Int J Antimicrob Agents; 2013 Dec; 42(6):537-43. PubMed ID: 24074727
[TBL] [Abstract][Full Text] [Related]
15. A Derivative of the Thiopeptide GE2270A Highly Selective against Propionibacterium acnes.
Fabbretti A; He CG; Gaspari E; Maffioli S; Brandi L; Spurio R; Sosio M; Jabes D; Donadio S
Antimicrob Agents Chemother; 2015 Aug; 59(8):4560-8. PubMed ID: 25987631
[TBL] [Abstract][Full Text] [Related]
16. [Antibacterial activity of nadifloxacin against Staphylococcus and Propionibacterium isolated from patients with dermatological infections].
Matsuzaki K; Omika K; Hasegawa M; Sato Y; Kobayashi I
Jpn J Antibiot; 2006 Aug; 59(4):316-20. PubMed ID: 17111596
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization, and in vitro antimicrobial assessment of nanocarrier based formulation of nadifloxacin for acne treatment.
Kumar A; Agarwal SP; Ahuja A; Ali J; Choudhry R; Baboota S
Pharmazie; 2011 Feb; 66(2):111-4. PubMed ID: 21434572
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes.
Gans EH; Kligman AM
J Dermatolog Treat; 2002 Sep; 13(3):107-10. PubMed ID: 12227872
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the antibacterial activity of rhapontigenin produced from rhapontin by biotransformation against Propionibacterium acnes.
Kim JK; Kim N; Lim YH
J Microbiol Biotechnol; 2010 Jan; 20(1):82-7. PubMed ID: 20134237
[TBL] [Abstract][Full Text] [Related]
20. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in vivo comparative study.
Leyden J; Kaidbey K; Levy SF
Am J Clin Dermatol; 2001; 2(4):263-6. PubMed ID: 11705253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
